Journal: Biomedical Reports

Article Title: Comparative study of biological characteristics of mesenchymal stem cells isolated from mouse bone marrow and peripheral blood

doi: 10.3892/br.2019.1236

Figure Lengend Snippet: Flow cytometry antibody panel used for characterization.

Article Snippet: Supplier CD29 PE HMs1-1 130-102-994 Miltenyi Biotec, Inc. CD44 FITC IM7.8.1 130-102-511 Miltenyi Biotec, Inc. CD105 PE MJ7/18 130-102-548 Miltenyi Biotec, Inc. CD90.2 FITC 30-H12 130-120-091 Miltenyi Biotec, Inc. CD146 FITC ME-9F1 130-102-230 Miltenyi Biotec, Inc. SCa-1 PE D7 130-102-832 Miltenyi Biotec, Inc. CD45 FITC 30F11.1 130-110-658 Miltenyi Biotec, Inc. CD140b PE APB5 130-118-457 Miltenyi Biotec, Inc. Open in a separate window CD, cluster of differentiation; PE, phycoethrin; FITC, fluorescein isothiocyanate.

Techniques: Flow Cytometry

Journal: Biomedical Reports

Article Title: Comparative study of biological characteristics of mesenchymal stem cells isolated from mouse bone marrow and peripheral blood

doi: 10.3892/br.2019.1236

Figure Lengend Snippet: Flow cytometric analysis of BM-MSCs and PB-MSCs. BM-MSCs were positive CD29 and negative for other markers, while PB-MSCs were positive for CD146, CD29, and CD140b and negative for Sca-1, CD44, CD45, CD90 and CD105. CD, cluster of differentiation; BM-MSCs, bone marrow-mesenchymal stromal cells; PB, peripheral blood; FITC, fluorescein isothiocyanate; PE, phycoerythrin.

Article Snippet: Supplier CD29 PE HMs1-1 130-102-994 Miltenyi Biotec, Inc. CD44 FITC IM7.8.1 130-102-511 Miltenyi Biotec, Inc. CD105 PE MJ7/18 130-102-548 Miltenyi Biotec, Inc. CD90.2 FITC 30-H12 130-120-091 Miltenyi Biotec, Inc. CD146 FITC ME-9F1 130-102-230 Miltenyi Biotec, Inc. SCa-1 PE D7 130-102-832 Miltenyi Biotec, Inc. CD45 FITC 30F11.1 130-110-658 Miltenyi Biotec, Inc. CD140b PE APB5 130-118-457 Miltenyi Biotec, Inc. Open in a separate window CD, cluster of differentiation; PE, phycoethrin; FITC, fluorescein isothiocyanate.

Techniques:

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Article Title: A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid

doi: 10.1002/alz.12061

Figure Lengend Snippet: a) CSF sPDGFRβ levels are significantly increased in individuals with CDR 0.5 (n=35) and CDR 1 (n=36) compared to cognitively normal CDR 0 individuals (n=14, young; n=59, older); significance by ANOVA with Tukey posthoc test, α=0.05. b-d) CSF sPDGFRβ relates to blood-brain barrier breakdown as shown by positive correlations with albumin quotient (Qalb) of CSF-to-plasma albumin levels (n=143) (b), CSF fibrinogen (n=144) (c), and CSF plasminogen (n=121) (d). e,f) Representative standard curve of PDGFRβ recombinant protein measured by Western blot (e) that is used to quantify sPDGFRβ levels in CSF samples by quantitative Western blot in panel f. There is a positive correlation of CSF sPDGFRβ levels measured by quantitative Western blot and the new MSD assay (n=93) (f). All panels plot single data points. In panel a, the box and whisker plots indicate the median value (horizontal line), the boxes indicate the interquartile range, and the whiskers indicate the minimum and maximum values. In panels b-d and f, Pearson correlation coefficient, r; significance by linear regression analysis.

Article Snippet: We used the following reagents: Standard bind 96-well plates (Catalog no. L15XA-3, MSD, Rockville, Maryland); High bind 96-well plates (Catalog no. L15XB-1/L11XB-1, MSD); the following capture antibodies : human PDGFRβ polyclonal goat immunoglobulin G (IgG) against amino acids 33–530 (Catalog no. AF385, R&D Systems, Minneapolis, MN); human PDGFRβ monoclonal mouse IgG raised against recombinant human PDGFRβ protein (Catalog no. MA5–15103, Thermo Fisher Scientific, Rockford, IL); human PDGFRβ polyclonal rabbit IgG against amino acids 54–72 (Catalog no. PA1–30317, Thermo Fisher Scientific); human PDGFRβ monoclonal mouse IgG against PDGFRβ protein in human skin fibroblast extracts (Catalog no. MAB1263, R&D Systems); human PDGFRβ monoclonal mouse IgG raised against amino acids 33–531 (Catalog no. MAB385, R&D Systems); the following detection antibodies : human PDGFRβ biotinylated polyclonal IgG against amino acids 33–530 (Catalog no. BAF385, R&D Systems); mouse PDGFRβ biotinylated polyclonal IgG against amino acids 32–530 and having approximately 40% cross-reactivity with recombinant human PDGFRβ (Catalog no. BAF1042, R&D Systems); human PDGFRβ polyclonal rabbit IgG raised against amino acids 54–72 (Catalog no. PA1–30317, Thermo Fisher Scientific); the following standard proteins : recombinant PDGFRβ human protein without catalytic activity domain (Catalog no. 10514H08H50, Invitrogen, Carlsbad, CA); carrier free recombinant human PDGFRβ Fc chimera (Catalog no. 385-PR/CF, R&D Systems); Blocker B (Catalog no. R93BB-2, MSD); Sulfo-tag labeled streptavidin (Catalog no. R32AD, MSD); Sulfo-tag labeled goat anti-rabbit IgG (Catalog no. R32AB, MSD); Read Buffer T with surfactant (Catalog no. R92TC-3, MSD); adhesive seal (Microseal ® , Catalog no. MSB1001, Bio-Rad, Hercules, CA).

Techniques: Clinical Proteomics, Recombinant, Western Blot, Whisker Assay

Journal: International Journal of Molecular Sciences

Article Title: Expression of Lumican and Osteopontin in Perivascular Areas of the Glioblastoma Peritumoral Niche and Its Value for Prognosis

doi: 10.3390/ijms26010192

Figure Lengend Snippet: CMA activity in PCs correlates with patient survival. ( A ) Representative images of peritumoral areas according to patient classification showing co-localization of puncta pattern expression of LAMP-2A protein (dark brown) with the PC marker α-SMA (pink) in microvessels of GB patients. Samples were classified as severe (highest α-SMA/LAMP-2A co-localization), moderate or mild (basal co-localization) according to the histological evaluation. A1 to A3 shows magnifications of microvessels (v). LAMP-2A co-localizationwith α-SMA + cells is marked with arrows. Scale bar: 100 µm. ( B ) Representative images of PCs marked with PDGFRβ (in red) in microvessels (v) showing co-localization of puncta pattern expression of LAMP-2A protein (in green) in peritumoral areas of severity classified GB patients. B1 to B3 show magnifications of PDGFRβ + cells. Positive co-localization (in yellow) is marked with arrows. Nuclei were stained with DAPI (blue). Scale bar: 100 µm. ( C ) Overall survival shown by Kaplan–Meier curves of the severity classification related to CMA activity in PCs; * p < 0.05: difference between mild and severe; # p < 0.05: difference between mild and moderate. ( D ) Age distribution by gender of the cohort of GB patients; **** p < 0.0001; ns indicates no significance. ( E ) Severity classification related to gender in the age range 30–65 years in the cohort of GB patients; **** p < 0.0001; ns indicates no significance.

Article Snippet: For fluorescent double-labeling of patient’s samples, goat anti-platelet-derived growth factor receptor beta (PDGFRβ; 1/250; BAF1042, R&D Systems, Barcelona, Spain), rabbit anti-LAMP-2A (1/1000; 51-2200, Invitrogen, Waltham, MA, USA) and mouse anti-RGS5 (1/150; MA5-25584, Invitrogen, Waltham, MA, USA) antibodies were used.

Techniques: Activity Assay, Expressing, Marker, Staining